<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00834106</url>
  </required_header>
  <id_info>
    <org_study_id>V501-041</org_study_id>
    <secondary_id>2009_532</secondary_id>
    <nct_id>NCT00834106</nct_id>
  </id_info>
  <brief_title>Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine to Investigate the Safety, and Efficacy in Chinese 20 - to 45-Years-Old Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to test the safety and effectiveness of Quadrivalent HPV (types 6, 11, 16, 18) L1 VLP
      vaccine against combined incidence of HPV 6/11/16/18-related persistent infection and vaccine
      type-specific genital disease among Chinese females between the ages of 20 and 45.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Base Study V501-041 duration was 30 months. The study was extended to further evaluate
      the efficacy of Quadrivalent HPV (Type 6, 11, 16, 18) L1 VLP (qHPV) vaccine against Cervical
      Intraepithelial Neoplasia Grade 2 (CIN 2), CIN 3, Adenocarcinoma In Situ (AIS), and/or
      cervical cancer. The efficacy was followed through the Month 78 visit, and the close-out
      visit was conducted at approximately Month 90 with only safety data collected
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 31, 2008</start_date>
  <completion_date type="Actual">September 30, 2016</completion_date>
  <primary_completion_date type="Actual">May 11, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Base Study: Combined Incidence of 6-Month Persistent Infection, Cervical Intraepithelial Neoplasia (CIN+), and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 45 Year Old Participants (Test of Hypothesis)</measure>
    <time_frame>From Day 1 until &gt;=25 cases accumulate, up to Month 30</time_frame>
    <description>The endpoint included pathology panel consensus diagnosis of 6-month persistent infection, CIN+ (including CIN grade 1, 2, or 3, cervical adenocarcinoma in situ (AIS), and cervical cancer), or external genital lesions related to HPV Types 6, 11, 16, or 18 detected by polymerase chain reaction (PCR) in an adjacent section from the same tissue block.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Base Study: Combined Incidence of 6-Month Persistent Infection, CIN+, and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 26 Years Old Participants (Test of Hypothesis)</measure>
    <time_frame>From Day 1 until &gt;=17 cases accumulate, up to Month 30</time_frame>
    <description>The endpoint included pathology panel consensus diagnosis of 6-month persistent infection, CIN+ (including CIN grade 1, 2, or 3, cervical adenocarcinoma in situ (AIS), and cervical cancer), or external genital lesions related to HPV Types 6, 11, 16, or 18 detected by PCR in an adjacent section from the same tissue block.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Entire Study: Combined Incidence of CIN2+ Related to HPV Types 16 or 18 in 20 to 45 Year Old Participants (End of Study Test of Hypothesis)</measure>
    <time_frame>Up to Month 78</time_frame>
    <description>The endpoint included pathology panel consensus diagnosis of CIN2+ (including CIN grade 2 or 3, AIS, and cervical cancer) related to HPV Types 16 or 18 detected by PCR in an adjacent section from the same tissue block.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Base Study: Percentage of Participants With One or More Solicited Injection-site Adverse Events</measure>
    <time_frame>Up to 15 days after any vaccination</time_frame>
    <description>An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor's product, is also an AE. Injection-site AEs were prompted on the Vaccination Report Card (VRC), which was completed by the participant for 15 days after each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Base Study: Percentage of Participants With One or More Systemic Adverse Events</measure>
    <time_frame>Up to 15 days after any vaccination</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor's product, is also an AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Base Study: Percentage of Participants Discontinued From Study Vaccination Due to an Adverse Event</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor's product, is also an AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Entire Study: Percentage of Participants With One or More Vaccine-related Serious Adverse Events</measure>
    <time_frame>Up to approximately 90 months</time_frame>
    <description>A serious adverse event (SAE) is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is an overdose or, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention. Related SAEs were those deemed possibly, probably, or definitely related to study vaccine or a study procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Entire Study: Percentage of Participants Who Died</measure>
    <time_frame>Up to approximately 90 months</time_frame>
    <description>The percentage of participants who died on study due to any cause, whether or not related to the investigational product, were reported for each arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Entire Study: Combined Incidence of 12-Month Persistent Infection, CIN+, and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 45 Year Old Participants (End of Study Update)</measure>
    <time_frame>Up to 78 months</time_frame>
    <description>The endpoint included pathology panel consensus diagnosis of 12-month persistent infection, CIN+ (including CIN grade 1, 2, or 3, cervical adenocarcinoma in situ (AIS), and cervical cancer), or external genital lesions related to HPV Types 6, 11, 16, or 18 detected by PCR in an adjacent section from the same tissue block.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Entire Study: Combined Incidence of 12-Month Persistent Infection, CIN+, and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 26 Year Old Participants (End of Study Update)</measure>
    <time_frame>Up to 78 months</time_frame>
    <description>The endpoint included pathology panel consensus diagnosis of 12-month persistent infection, CIN+ (including CIN grade 1, 2, or 3, cervical adenocarcinoma in situ (AIS), and cervical cancer), or external genital lesions related to HPV Types 6, 11, 16, or 18 detected by PCR in an adjacent section from the same tissue block.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3006</enrollment>
  <condition>HPV Infections</condition>
  <arm_group>
    <arm_group_label>qHPV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine</intervention_name>
    <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine injection at Day 1, Month 2, and Month 6.</description>
    <arm_group_label>qHPV</arm_group_label>
    <other_name>Gardasil ™</other_name>
    <other_name>V501</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: placebo (unspecified)</intervention_name>
    <description>Aluminum-containing Vaccine placebo injection at Day 1, Month 2, and Month 6.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women between the ages of 20 and 45

          -  Have used effective contraception for 2 weeks prior to starting in the study

          -  Does not have a temperature within 24 hours before the first injection

        Exclusion Criteria:

          -  Prior history of genital warts

          -  More than 4 lifetime sexual partners

          -  Have undergone hysterectomy

          -  Have active cervical disease or history of cervical disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2009</study_first_submitted>
  <study_first_submitted_qc>January 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <results_first_submitted>September 12, 2017</results_first_submitted>
  <results_first_submitted_qc>September 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 12, 2017</results_first_posted>
  <disposition_first_submitted>April 25, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>April 25, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 3, 2013</disposition_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV 6/11/16/18 Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were stratified by age before randomization: 20 to 26 years of age and 27 to 45 years of age.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>qHPV</title>
          <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Base Study (Day 1 to Month 30)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1503">Randomized participants</participants>
                <participants group_id="P2" count="1503">Randomized participants</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="1503"/>
                <participants group_id="P2" count="1503"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Vaccinations</title>
              <participants_list>
                <participants group_id="P1" count="1473"/>
                <participants group_id="P2" count="1463"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1401">Completed Month 30 follow-up</participants>
                <participants group_id="P2" count="1358">Completed Month 30 follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="145"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Extension Study (Month 42 to Month 90)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1404">Some participants missed the Month 30 visit but returned for the Month 42 visit</participants>
                <participants group_id="P2" count="1368">Some participants missed the Month 30 visit but returned for the Month 42 visit</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1308"/>
                <participants group_id="P2" count="1294"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>qHPV</title>
          <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1503"/>
            <count group_id="B2" value="1503"/>
            <count group_id="B3" value="3006"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.7" spread="6.4"/>
                    <measurement group_id="B2" value="28.7" spread="6.4"/>
                    <measurement group_id="B3" value="28.7" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>20 to 26 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="923"/>
                    <measurement group_id="B2" value="917"/>
                    <measurement group_id="B3" value="1840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>27 to 45 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="580"/>
                    <measurement group_id="B2" value="586"/>
                    <measurement group_id="B3" value="1166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1503"/>
                    <measurement group_id="B2" value="1503"/>
                    <measurement group_id="B3" value="3006"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1503"/>
                    <measurement group_id="B2" value="1503"/>
                    <measurement group_id="B3" value="3006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Base Study: Combined Incidence of 6-Month Persistent Infection, Cervical Intraepithelial Neoplasia (CIN+), and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 45 Year Old Participants (Test of Hypothesis)</title>
        <description>The endpoint included pathology panel consensus diagnosis of 6-month persistent infection, CIN+ (including CIN grade 1, 2, or 3, cervical adenocarcinoma in situ (AIS), and cervical cancer), or external genital lesions related to HPV Types 6, 11, 16, or 18 detected by polymerase chain reaction (PCR) in an adjacent section from the same tissue block.</description>
        <time_frame>From Day 1 until &gt;=25 cases accumulate, up to Month 30</time_frame>
        <population>The population analyzed included participants who received the full vaccination series, had at least 1 visit after Month 7, had no general protocol violations, and were seronegative at Baseline and polymerase chain reaction-negative from Baseline through Month 7 for HPV types 6, 11, 16, and 18.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV</title>
            <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: Combined Incidence of 6-Month Persistent Infection, Cervical Intraepithelial Neoplasia (CIN+), and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 45 Year Old Participants (Test of Hypothesis)</title>
          <description>The endpoint included pathology panel consensus diagnosis of 6-month persistent infection, CIN+ (including CIN grade 1, 2, or 3, cervical adenocarcinoma in situ (AIS), and cervical cancer), or external genital lesions related to HPV Types 6, 11, 16, or 18 detected by polymerase chain reaction (PCR) in an adjacent section from the same tissue block.</description>
          <population>The population analyzed included participants who received the full vaccination series, had at least 1 visit after Month 7, had no general protocol violations, and were seronegative at Baseline and polymerase chain reaction-negative from Baseline through Month 7 for HPV types 6, 11, 16, and 18.</population>
          <units>Cases per 100 person-years of follow-up</units>
          <param>Number</param>
          <units_analyzed>person-years</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1281"/>
                <count group_id="O2" value="1249"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>person-years</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2491"/>
                <count group_id="O2" value="2389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine efficacy</param_type>
            <param_value>76.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>43.7</ci_lower_limit>
            <ci_upper_limit>91.1</ci_upper_limit>
            <estimate_desc>Vaccine efficacy = 100 * [1 - (incidence rate with V501 / incidence rate with placebo)]. The pre-specified success criterion was that the lower bound of the 95% confidence interval for vaccine efficacy excludes 0%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Base Study: Combined Incidence of 6-Month Persistent Infection, CIN+, and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 26 Years Old Participants (Test of Hypothesis)</title>
        <description>The endpoint included pathology panel consensus diagnosis of 6-month persistent infection, CIN+ (including CIN grade 1, 2, or 3, cervical adenocarcinoma in situ (AIS), and cervical cancer), or external genital lesions related to HPV Types 6, 11, 16, or 18 detected by PCR in an adjacent section from the same tissue block.</description>
        <time_frame>From Day 1 until &gt;=17 cases accumulate, up to Month 30</time_frame>
        <population>The population analyzed included participants 20 to 26 years old at Baseline who received the full vaccination series, had at least 1 visit after Month 7, had no general protocol violations, and were seronegative at Baseline and polymerase chain reaction-negative from Baseline through Month 7 for HPV types 6, 11, 16, and 18.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV</title>
            <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: Combined Incidence of 6-Month Persistent Infection, CIN+, and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 26 Years Old Participants (Test of Hypothesis)</title>
          <description>The endpoint included pathology panel consensus diagnosis of 6-month persistent infection, CIN+ (including CIN grade 1, 2, or 3, cervical adenocarcinoma in situ (AIS), and cervical cancer), or external genital lesions related to HPV Types 6, 11, 16, or 18 detected by PCR in an adjacent section from the same tissue block.</description>
          <population>The population analyzed included participants 20 to 26 years old at Baseline who received the full vaccination series, had at least 1 visit after Month 7, had no general protocol violations, and were seronegative at Baseline and polymerase chain reaction-negative from Baseline through Month 7 for HPV types 6, 11, 16, and 18.</population>
          <units>Cases per 100 person-years of follow-up</units>
          <param>Number</param>
          <units_analyzed>person-years</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="760"/>
                <count group_id="O2" value="733"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>person-years</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1461"/>
                <count group_id="O2" value="1376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine efficacy</param_type>
            <param_value>82.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>38.3</ci_lower_limit>
            <ci_upper_limit>96.7</ci_upper_limit>
            <estimate_desc>Vaccine efficacy = 100 * [1 - (incidence rate with V501 / incidence rate with placebo)]. The pre-specified success criterion was that the lower bound of the 95% confidence interval for vaccine efficacy excludes 0%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Entire Study: Combined Incidence of CIN2+ Related to HPV Types 16 or 18 in 20 to 45 Year Old Participants (End of Study Test of Hypothesis)</title>
        <description>The endpoint included pathology panel consensus diagnosis of CIN2+ (including CIN grade 2 or 3, AIS, and cervical cancer) related to HPV Types 16 or 18 detected by PCR in an adjacent section from the same tissue block.</description>
        <time_frame>Up to Month 78</time_frame>
        <population>The population analyzed included participants who received the full vaccination series, had at least 1 visit after Month 7, had no general protocol violations, and were seronegative at Baseline and polymerase chain reaction-negative from Baseline through Month 7 for HPV types 16 and 18.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV</title>
            <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Entire Study: Combined Incidence of CIN2+ Related to HPV Types 16 or 18 in 20 to 45 Year Old Participants (End of Study Test of Hypothesis)</title>
          <description>The endpoint included pathology panel consensus diagnosis of CIN2+ (including CIN grade 2 or 3, AIS, and cervical cancer) related to HPV Types 16 or 18 detected by PCR in an adjacent section from the same tissue block.</description>
          <population>The population analyzed included participants who received the full vaccination series, had at least 1 visit after Month 7, had no general protocol violations, and were seronegative at Baseline and polymerase chain reaction-negative from Baseline through Month 7 for HPV types 16 and 18.</population>
          <units>Cases per 100 person-years of follow-up</units>
          <param>Number</param>
          <units_analyzed>person-years</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1265"/>
                <count group_id="O2" value="1237"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>person-years</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6992"/>
                <count group_id="O2" value="6789"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0072</p_value>
            <method>Exact test, 1-sided</method>
            <param_type>Vaccine efficacy</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>32.3</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>Vaccine efficacy = 100 * [1 - (incidence rate with V501 / incidence rate with placebo)]. The pre-specified success criterion was that the lower bound of the 95% confidence interval for vaccine efficacy excludes 0%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Base Study: Percentage of Participants With One or More Solicited Injection-site Adverse Events</title>
        <description>An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor’s product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor’s product, is also an AE. Injection-site AEs were prompted on the Vaccination Report Card (VRC), which was completed by the participant for 15 days after each vaccination.</description>
        <time_frame>Up to 15 days after any vaccination</time_frame>
        <population>All vaccinated participants with safety follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV</title>
            <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: Percentage of Participants With One or More Solicited Injection-site Adverse Events</title>
          <description>An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor’s product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor’s product, is also an AE. Injection-site AEs were prompted on the Vaccination Report Card (VRC), which was completed by the participant for 15 days after each vaccination.</description>
          <population>All vaccinated participants with safety follow-up</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1499"/>
                <count group_id="O2" value="1498"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6"/>
                    <measurement group_id="O2" value="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Base Study: Percentage of Participants With One or More Systemic Adverse Events</title>
        <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor’s product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor’s product, is also an AE.</description>
        <time_frame>Up to 15 days after any vaccination</time_frame>
        <population>All vaccinated participants with safety follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV</title>
            <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: Percentage of Participants With One or More Systemic Adverse Events</title>
          <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor’s product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor’s product, is also an AE.</description>
          <population>All vaccinated participants with safety follow-up</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1499"/>
                <count group_id="O2" value="1498"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.4"/>
                    <measurement group_id="O2" value="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Base Study: Percentage of Participants Discontinued From Study Vaccination Due to an Adverse Event</title>
        <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor’s product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor’s product, is also an AE.</description>
        <time_frame>Up to 6 months</time_frame>
        <population>All vaccinated participants with safety follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV</title>
            <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: Percentage of Participants Discontinued From Study Vaccination Due to an Adverse Event</title>
          <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor’s product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor’s product, is also an AE.</description>
          <population>All vaccinated participants with safety follow-up</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1499"/>
                <count group_id="O2" value="1498"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Entire Study: Percentage of Participants With One or More Vaccine-related Serious Adverse Events</title>
        <description>A serious adverse event (SAE) is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is an overdose or, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention. Related SAEs were those deemed possibly, probably, or definitely related to study vaccine or a study procedure.</description>
        <time_frame>Up to approximately 90 months</time_frame>
        <population>All vaccinated participants with safety follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV</title>
            <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Entire Study: Percentage of Participants With One or More Vaccine-related Serious Adverse Events</title>
          <description>A serious adverse event (SAE) is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is an overdose or, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention. Related SAEs were those deemed possibly, probably, or definitely related to study vaccine or a study procedure.</description>
          <population>All vaccinated participants with safety follow-up</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1499"/>
                <count group_id="O2" value="1498"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Entire Study: Percentage of Participants Who Died</title>
        <description>The percentage of participants who died on study due to any cause, whether or not related to the investigational product, were reported for each arm</description>
        <time_frame>Up to approximately 90 months</time_frame>
        <population>All vaccinated participants with safety follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV</title>
            <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Entire Study: Percentage of Participants Who Died</title>
          <description>The percentage of participants who died on study due to any cause, whether or not related to the investigational product, were reported for each arm</description>
          <population>All vaccinated participants with safety follow-up</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1499"/>
                <count group_id="O2" value="1498"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Entire Study: Combined Incidence of 12-Month Persistent Infection, CIN+, and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 45 Year Old Participants (End of Study Update)</title>
        <description>The endpoint included pathology panel consensus diagnosis of 12-month persistent infection, CIN+ (including CIN grade 1, 2, or 3, cervical adenocarcinoma in situ (AIS), and cervical cancer), or external genital lesions related to HPV Types 6, 11, 16, or 18 detected by PCR in an adjacent section from the same tissue block.</description>
        <time_frame>Up to 78 months</time_frame>
        <population>The population analyzed included participants who received the full vaccination series, had at least 1 visit after Month 7, had no general protocol violations, and were seronegative at Baseline and polymerase chain reaction-negative from Baseline through Month 7 for HPV types 6, 11, 16, and 18.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV</title>
            <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Entire Study: Combined Incidence of 12-Month Persistent Infection, CIN+, and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 45 Year Old Participants (End of Study Update)</title>
          <description>The endpoint included pathology panel consensus diagnosis of 12-month persistent infection, CIN+ (including CIN grade 1, 2, or 3, cervical adenocarcinoma in situ (AIS), and cervical cancer), or external genital lesions related to HPV Types 6, 11, 16, or 18 detected by PCR in an adjacent section from the same tissue block.</description>
          <population>The population analyzed included participants who received the full vaccination series, had at least 1 visit after Month 7, had no general protocol violations, and were seronegative at Baseline and polymerase chain reaction-negative from Baseline through Month 7 for HPV types 6, 11, 16, and 18.</population>
          <units>Cases per 100 person-years of follow-up</units>
          <param>Number</param>
          <units_analyzed>person-years</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1281"/>
                <count group_id="O2" value="1249"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>person-years</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8515"/>
                <count group_id="O2" value="8015"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine efficacy</param_type>
            <param_value>91.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>79.8</ci_lower_limit>
            <ci_upper_limit>97.4</ci_upper_limit>
            <estimate_desc>Vaccine efficacy = 100 * [1 - (incidence rate with V501 / incidence rate with placebo)].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Entire Study: Combined Incidence of 12-Month Persistent Infection, CIN+, and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 26 Year Old Participants (End of Study Update)</title>
        <description>The endpoint included pathology panel consensus diagnosis of 12-month persistent infection, CIN+ (including CIN grade 1, 2, or 3, cervical adenocarcinoma in situ (AIS), and cervical cancer), or external genital lesions related to HPV Types 6, 11, 16, or 18 detected by PCR in an adjacent section from the same tissue block.</description>
        <time_frame>Up to 78 months</time_frame>
        <population>The population analyzed included participants 20 to 26 years of age at Baseline who received the full vaccination series, had at least 1 visit after Month 7, had no general protocol violations, and were seronegative at Baseline and polymerase chain reaction-negative from Baseline through Month 7 for HPV types 6, 11, 16, and 18.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV</title>
            <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Entire Study: Combined Incidence of 12-Month Persistent Infection, CIN+, and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 26 Year Old Participants (End of Study Update)</title>
          <description>The endpoint included pathology panel consensus diagnosis of 12-month persistent infection, CIN+ (including CIN grade 1, 2, or 3, cervical adenocarcinoma in situ (AIS), and cervical cancer), or external genital lesions related to HPV Types 6, 11, 16, or 18 detected by PCR in an adjacent section from the same tissue block.</description>
          <population>The population analyzed included participants 20 to 26 years of age at Baseline who received the full vaccination series, had at least 1 visit after Month 7, had no general protocol violations, and were seronegative at Baseline and polymerase chain reaction-negative from Baseline through Month 7 for HPV types 6, 11, 16, and 18.</population>
          <units>Cases per 100 person-years of follow-up</units>
          <param>Number</param>
          <units_analyzed>person-years</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="760"/>
                <count group_id="O2" value="733"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>person-years</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4952"/>
                <count group_id="O2" value="4559"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine efficacy</param_type>
            <param_value>93.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>72.9</ci_lower_limit>
            <ci_upper_limit>99.2</ci_upper_limit>
            <estimate_desc>Vaccine efficacy = 100 * [1 - (incidence rate with V501 / incidence rate with placebo)].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to approximately 90 months</time_frame>
      <desc>All vaccinated participants with safety follow-up</desc>
      <group_list>
        <group group_id="E1">
          <title>qHPV</title>
          <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo administered by intramuscular injection on Day 1, Month 2, and Month 6</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="1499"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Thyroid Mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Meniscus Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Ulna Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign Hydatidiform Mole</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Breast Fibroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Endometrial Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Fibroadenoma Of Breast</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Intraductal Papilloma Of Breast</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Intraductal Proliferative Breast Lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Ovarian Cancer Stage Iii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Ovarian Germ Cell Teratoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Papillary Thyroid Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Phyllodes Tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Vaginal Cancer Stage 0</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal Tunnel Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Trigeminal Neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Abortion Missed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Cephalo-Pelvic Disproportion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Ectopic Pregnancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1499"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Foetal Damage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Foetal Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Gestational Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Placenta Accreta</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Kidney Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Urethral Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical Dysplasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1499"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Cervical Polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Endometrial Hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Fallopian Tube Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Pelvic Fluid Collection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Uterine Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Uterine Polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epiglottic Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Interstitial Lung Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Pulmonary Mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatomyositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Appendicectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Ectopic Pregnancy Termination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Fallopian Tube Operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Haemorrhoid Operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Labour Induction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Myomectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Synovial Cyst Removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Thyroid Adenoma Removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Thyroid Nodule Removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Uterine Polypectomy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1499"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="876" subjects_at_risk="1499"/>
                <counts group_id="E2" subjects_affected="799" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="106" subjects_affected="89" subjects_at_risk="1499"/>
                <counts group_id="E2" events="105" subjects_affected="94" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="122" subjects_affected="100" subjects_at_risk="1499"/>
                <counts group_id="E2" events="106" subjects_affected="95" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="310" subjects_affected="227" subjects_at_risk="1499"/>
                <counts group_id="E2" events="247" subjects_affected="193" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" events="233" subjects_affected="176" subjects_at_risk="1499"/>
                <counts group_id="E2" events="163" subjects_affected="133" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Injection Site Induration</sub_title>
                <counts group_id="E1" events="151" subjects_affected="115" subjects_at_risk="1499"/>
                <counts group_id="E2" events="76" subjects_affected="64" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="778" subjects_affected="494" subjects_at_risk="1499"/>
                <counts group_id="E2" events="450" subjects_affected="346" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Injection Site Pruritus</sub_title>
                <counts group_id="E1" events="145" subjects_affected="113" subjects_at_risk="1499"/>
                <counts group_id="E2" events="83" subjects_affected="77" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" events="220" subjects_affected="160" subjects_at_risk="1499"/>
                <counts group_id="E2" events="92" subjects_affected="78" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="493" subjects_affected="388" subjects_at_risk="1499"/>
                <counts group_id="E2" events="432" subjects_affected="352" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="307" subjects_affected="224" subjects_at_risk="1499"/>
                <counts group_id="E2" events="185" subjects_affected="153" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="274" subjects_affected="218" subjects_at_risk="1499"/>
                <counts group_id="E2" events="240" subjects_affected="193" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="103" subjects_affected="84" subjects_at_risk="1499"/>
                <counts group_id="E2" events="99" subjects_affected="91" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

